Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28945607 | 0.98 | PRMT1 (0.52) | PRMT1ADRA1AMAPK1KDM4EHIF1A | |
| SCHEMBL27130042 | 0.98 | PRMT1 (0.52) | PRMT1ADRA1AMAPK1KDM4EHIF1A | |
| SCHEMBL25575179 | 0.89 | CASP2 (0.47) | PRMT1ADRA1AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL3651893 | 0.84 | — | — | |
| SCHEMBL3174690 | 0.84 | KDM4E (0.50) | PRMT1ADRA1AMAPK1KDM4EHIF1A | |
| SCHEMBL29916467 | 0.82 | PRMT1 (0.70) | PRMT1ADRA1AMAPK1PLA2G2ALMNA | |
| SCHEMBL19683940 | 0.82 | PRMT1 (0.44) | PRMT1ADRA1AMAPK1KDM4EHIF1A | |
| SCHEMBL453216 | 0.81 | KDM4E (0.55) | PRMT1ADRA1AMAPK1KDM4EHIF1A | |
| SCHEMBL28569684 | 0.81 | KDM4E (0.55) | PRMT1ADRA1AMAPK1KDM4EHIF1A | |
| SCHEMBL20836564 | 0.81 | KDM4E (0.55) | PRMT1ADRA1AMAPK1KDM4EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487492-B2 | Dibenzothiazepine derivatives and their use in the treatment of CNS disorders | NUMEDICUS LIMITED (GB) | 2016-11-08 | — | — | US | disclosed |
| EP-2699559-B1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | NUMEDICUS LTD (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-20140243317-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | NUMEDICUS LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| EP-2699559-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | Numedicus Limited (GB) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143703-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | NUMEDICUS LIMITED (GB) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243317-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SLC6A3, DRD1, AVPR2 | PRMT1 928/4885ADRA1A 249/4885MAPK1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.